DARA BioSciences is a North Carolina-based development-stage pharmaceutical company that acquires promising therapeutic molecules and medical technologies directly or through investment in established companies. The company focuses its therapeutic development efforts on small molecules from late preclinical development through Phase 2 clinical trials. It has a portfolio of drug candidates for neuropathic pain, type 2 diabetes and psoriasis. DARA continues to build a diverse pipeline, including candidates for the treatment of metabolic diseases and pain. The company is currently conducting a Phase 2a trial for the treatment of neuropathic pain with KRN5500 and is in later stage preclinical development with a number of other programs. DARA BioSciences is headquartered in Raleigh, N.C.